Fortrea Holdings Inc. (FTRE) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development.
Is Fortrea Holdings Inc. stock overvalued or undervalued in 2026?
As of October 30, 2026, Fortrea Holdings Inc. (FTRE) trades at $21.29 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Fortrea Holdings Inc.
Market cap $2B · 52 weeks $9 – $26 (18 % below the high) · P/E no earnings · 2027 est. P/E 20.1× · Dividend none · Next earnings February 25, 2027 · expected EPS $0.23 · Closing price, Oct 30 · accounts published Oct 29.
- Valuation: P/Sales 0.5× (no earnings).
- Balance sheet: Distress zone (fragile).
- Earnings: 5 of 8 (uneven).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 1 of 4 pass
- Total Debt 6.9×, fails.
- R&D / Market cap 0.0 %, fails.
- Market cap / Cash 11.1×, fails.
- Annual cash burn $1.24, passes.
Against its peers (reference peers) — Fortrea Holdings Inc.: P/E —; EV/EBITDA 27.9×; ROIC 2.3 %; $2.0B. Vericel Corporation (P/E 86.1×; EV/EBITDA 52.3×; ROIC 3.8 %; $2.1B), Lakefront Biotherapeutics N.V. (P/E 3.9×; EV/EBITDA 5.3×; ROIC 11.6 %; $2.1B), Aurinia Pharmaceuticals Inc. (P/E 7.3×; EV/EBITDA 11.4×; ROIC 20.9 %; $2.2B).
Profitability
| Return on Equity | -12.81% |
| Return on Invested Capital | 2.34% |
| Return on Assets | -2.51% |
| Gross Margin | 18.54% |
| Operating Margin | 1.57% |
| Net Margin | -2.58% |
Financial Health
| Debt / Equity | 2.10 |
| Current Ratio | 0.97 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 0.68 |
Price Performance
| 1 month | +6.45% |
| 3 months | +18.34% |
| Year-to-date | +23.42% |
| 1 year | +103.54% |
| 3 years | -28.68% |
Related companies: XNCR · MRVI · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX
Explore sector: Healthcare · Biotechnology
More sections of FTRE: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks